Swiss start up, NovaGo Therapeutics, co-founded by Zurich University professor Martin Schwab and Neurimmune Holdings AG founder and president Roger Nitsch, is based on Schwab’s discovery of inhibitors of neurite growth which cause the absent regeneration of injured fiber tracts in the central nervous system.
It has since been demonstrated that blocking the most potent of those nerve fiber growth inhibitors, Nogo-A, led to regeneration...







